Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the provided label excerpts: several core indication/non-rescue and mouth-rinsing/thrush items are supported. However, at least one dosing-device detail is only partially supported, and multiple clinically relevant safety/counseling elements (notably contraindications/boxed warnings and broader warnings) are not verifiably addressed within the supplied label sections, creating material label-adherence uncertainty.
Category Scores
Accurate Statements
Arnuity Ellipta is a brand-name inhaled corticosteroid (ICS).
Supported by label text: 'ARNUITY ELLIPTA contains fluticasone furoate, an ICS.' (5.1; also referenced in available material).
Arnuity Ellipta contains fluticasone furoate.
Supported by label text: 'ARNUITY ELLIPTA contains fluticasone furoate...' (5.1).
Arnuity Ellipta is used as maintenance therapy to help prevent asthma symptoms.
Supported by indication: 'indicated for the maintenance treatment of asthma...' (1 Indications and Usage).
Arnuity Ellipta is used for long-term control of asthma.
Supported by indication wording: 'maintenance treatment of asthma...' (1 Indications and Usage).
Arnuity Ellipta is not a rescue inhaler for sudden breathing problems.
Supported by limitation of use: 'NOT indicated for the relief of acute bronchospasm.' (1 Indications and Usage) and 'not indicated for the relief of acute symptoms... as rescue therapy...' (5.2).
Arnuity Ellipta is usually taken once daily as directed by a clinician.
Supported by dosing: 'once daily by oral inhalation.' (2.2).
Patients are commonly advised to rinse their mouth and spit after inhalation to help reduce throat irritation and oral side effects.
Supported by counseling: 'rinse his/her mouth with water without swallowing following administration...' (5.1) and 'rinse the mouth with water without swallowing after inhalation to help reduce the risk of thrush.' (17).
Common reported side effects with inhaled steroids can include oral yeast (thrush).
Supported by label: 'Oropharyngeal Candidiasis' and 'Localized infections of the mouth and pharynx with Candida albicans...' (5.1; also listed in 6 as a steroid effect).
Contact a clinician if symptoms suggest infection or if asthma control worsens.
Partially supported: label includes contacting physicians for worsening/not improving after 2 weeks and immediate medical attention for significant decreases/loss of control; infection-specific contact is not explicitly phrased as 'suggest infection' in the provided excerpts (17 plus 5.1 mentions treating candida if it develops).
Unsupported Statements
Arnuity Ellipta helps reduce asthma flare-ups and symptoms by controlling airway inflammation.
Not supported by the supplied label excerpts. The provided sections do not state this mechanism or these specific flare-up/control-inflammation phrasing.
Arnuity Ellipta is delivered through the Ellipta inhaler.
Only partially supported: the provided label text confirms 'once daily by oral inhalation' (2.2) but does not explicitly state the specific device name 'Ellipta inhaler' in the excerpt provided.
Common reported side effects with inhaled steroids include hoarseness or sore throat.
Not supported by the supplied label excerpts; no hoarseness/sore throat claims appear in the provided sections.
Contradictions
Important Omissions
Presence/absence and details of boxed warning(s), contraindications, and broader warnings/precautions (beyond the provided thrush/non-acute and some counseling excerpts) were not evaluated because the AI response excerpts/claims did not address these label sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related claims are supported (non-rescue use; mouth rinsing; thrush), but at least one device/delivery detail is only partially supported and other major safety labeling domains (e.g., contraindications/boxed warnings/complete warnings) are not verifiably addressed in the provided material, leaving material label-adherence uncertainty.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Delivery-device wording and multiple safety/AE statements are either only partially supported or not supported by the supplied label excerpts; broader label domains (contraindications/boxed warnings) were not addressed.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label sections (e.g., cite 'once daily by oral inhalation' rather than asserting the specific 'Ellipta inhaler' phrasing; remove unsupported hoarseness/sore throat and inflammation/flare-up mechanism claims; ensure coverage of contraindications/boxed warnings/warnings if making safety claims).